Moderna, Inc. (NASDAQ:MRNA) revealed topline results on Wednesday from a Phase 3 trial evaluating the efficacy of mRNA-1647, the company’s investigational cytomegalovirus (CMV) vaccine. CMV is a herpes virus. Those who are pregnant or have compromised immune systems are most at risk from CMV.

The study did not meet its primary efficacy endpoint of preventing CMV infection in seronegative female participants of childbearing age (16-40 years of age).

Moderna will discontinue its congenital CMV clinical development program.

Also Read: Moderna Reports Promising Response Rates For Skin Cancer Combo Therapy In Resistant Patients

The Phase 3 trial included approximately 7,500 women. Vaccine efficacy against primary CMV infection in healthy women was well below the company’s target, ranging from 6% to 23% depending on the case definition used.

“We are clearly disappointed ...